Your Messages Inbox
Your Article Summary
See Latest ArticlesGlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
GlaxoSmithKline, 11/03/09
GlaxoSmithKline PLC and Human Genome Sciences, Inc. announced that Benlysta met the primary endpoint in BLISS–76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus. BLISS–76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09
Article Search
Sponsor